Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Journal for Immunotherapy of Cancer
|
August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma
Sapna P Patel, Gina R Petroni, Jason Roszik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 17, 2010
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines
Craig L Slingluff, Gina R Petroni, Mark E Smolkin, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 25, 2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
Kimberly A Chianese-Bullock, Jennifer Pressley, Courtney Garbee, et al.
Cancer Immunology, Immunotherapy : CII
|
November 20, 2015
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites
Craig L Slingluff, Gina R Petroni, Walter C Olson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer
Costanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
Cancer Immunology, Immunotherapy : CII
|
August 15, 2016
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Ileana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2004
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
Craig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Molecular Oncology
|
May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance
Costanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Cancer Immunology, Immunotherapy : CII
|
August 15, 2016
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Ileana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal for Immunotherapy of Cancer
|
January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)
Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Journal for Immunotherapy of Cancer
|
August 20, 2021
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma
Sapna P Patel, Gina R Petroni, Jason Roszik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 17, 2010
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines
Craig L Slingluff, Gina R Petroni, Mark E Smolkin, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
February 25, 2005
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
Kimberly A Chianese-Bullock, Jennifer Pressley, Courtney Garbee, et al.
Cancer Immunology, Immunotherapy : CII
|
November 20, 2015
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites
Craig L Slingluff, Gina R Petroni, Walter C Olson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer
Costanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
Cancer Immunology, Immunotherapy : CII
|
August 15, 2016
Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
Ileana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2004
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
Craig L Slingluff, Gina R Petroni, Galina V Yamshchikov, et al.
Molecular Oncology
|
May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance
Costanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Cancer Immunology, Immunotherapy : CII
|
August 15, 2016
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases
Ileana S Mauldin, Nolan A Wages, Anne M Stowman, et al.
Journal for Immunotherapy of Cancer
|
January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)
Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Page
of 6